KRAS and neoplasm: Our findings are expected to establish an oncogene‐driven combinatorial treatment strategy to potentiate the anti‐tumor activity of both CDK9i and KRAS signaling inhibitors, while concurrently mitigating immunosuppression and overcoming drug resistance.